Berkshire Hathaway (NYSE:BRK.B) Stock Rating Upgraded by ValuEngine

Share on StockTwits

Berkshire Hathaway (NYSE:BRK.B) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Friday, ValuEngine reports.

Separately, Zacks Investment Research cut Berkshire Hathaway from a “hold” rating to a “sell” rating and set a $218.00 price target for the company. in a report on Monday, October 14th.

Shares of NYSE BRK.B traded down $1.43 during trading hours on Friday, hitting $221.31. 3,253,521 shares of the company’s stock were exchanged, compared to its average volume of 3,882,753. Berkshire Hathaway has a 1-year low of $186.10 and a 1-year high of $223.59. The stock has a market capitalization of $541.39 billion, a price-to-earnings ratio of 22.02, a PEG ratio of 3.00 and a beta of 0.84. The company’s 50-day moving average price is $210.28 and its 200-day moving average price is $207.37.

About Berkshire Hathaway

Berkshire Hathaway Inc, through its subsidiaries engages in insurance, freight rail transportation, and utility businesses. It provides property and casualty insurance and reinsurance, as well as life, accident, and health reinsurance; and operates railroad systems in North America. The company also generates, transmits, and distributes electricity primarily from solar, wind, geothermal, and hydro sources; operates natural gas distribution and storage facilities, interstate pipelines, and compressor and meter stations; and holds interest in coal mining assets.

See Also: What is a good dividend yield?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Berkshire Hathaway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Berkshire Hathaway and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Crispr Therapeutics  Raised to “Buy” at BidaskClub
Crispr Therapeutics Raised to “Buy” at BidaskClub
Liberum Capital Trims Tyman  Target Price to GBX 300
Liberum Capital Trims Tyman Target Price to GBX 300
Kier Group  Earns Buy Rating from Liberum Capital
Kier Group Earns Buy Rating from Liberum Capital
Revolve Group  Hits New 52-Week Low on Analyst Downgrade
Revolve Group Hits New 52-Week Low on Analyst Downgrade
Bayan Token 24-Hour Volume Reaches $684.00
Bayan Token 24-Hour Volume Reaches $684.00
sUSD  Achieves Market Capitalization of $9.07 Million
sUSD Achieves Market Capitalization of $9.07 Million


© 2006-2019 Ticker Report